The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients
| Autor: | Pierre Drouin, Irene Delbachian, Philip Bohme, Nathalie Cugnardey, Philippe Lehert, Laurent Meyer, Bruno Guerci |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
Blood Glucose Male medicine.medical_specialty Randomization Time Factors Endocrinology Diabetes and Metabolism medicine.medical_treatment Placebo Gastroenterology Placebos chemistry.chemical_compound Insulin Infusion Systems Double-Blind Method Oral administration Diabetes mellitus Internal medicine Internal Medicine Medicine Humans Hypoglycemic Agents Advanced and Specialized Nursing Glycated Hemoglobin Type 1 diabetes C-Peptide Dose-Response Relationship Drug business.industry C-peptide Insulin medicine.disease Metformin Endocrinology Diabetes Mellitus Type 1 chemistry Drug Therapy Combination Female business medicine.drug |
| Zdroj: | Diabetes care. 25(12) |
| ISSN: | 0149-5992 |
| Popis: | OBJECTIVE—This study was designed to assess the insulin-sparing effect of oral administration of metformin along with a continuous subcutaneous insulin infusion (CSII) for the treatment of type 1 diabetic patients. RESEARCH DESIGN AND METHODS—A total of 62 patients (25 women and 37 men) were studied in a monocenter, randomized, double-blind placebo-controlled study, comparing metformin (850 mg b.i.d.) with placebo in association with CSII during a 6-month period. RESULTS—Treatment with metformin was associated with a reduction in daily insulin requirements between V0 and V6 of −4.3 ± 9.9 units (−7.8 ± 18%) compared with an increase with placebo treatment of 1.7 ± 8.3 units (2.8 ± 12.7%) (P = 0.0043). A decrease in basal requirement of insulin was also observed in patients treated with metformin of −2.6 ± 3.2 units (−7.9 ± 23.8%) compared with an increase with placebo treatment of 1.9 ± 5.7 units (8.8 ± 27.1%) (P = 0.023). HbA1c remained unchanged in treatment with metformin and placebo between V0 and V6. The number of hypoglycemic events ( CONCLUSIONS—Metformin was found to be a safe insulin-sparing agent, when used in combination with CSII for the treatment of type 1 diabetes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|